Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03383874 · ClinicalTrials.gov registry record · Phase 3
A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania
A Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 67
- Enrollment target
NCT03383874 is a Phase 3 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 67 participants.
The verdict
NCT03383874, a Phase 3 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 67 participants
- Enrollment target
Study Summary
This will be a 24-week, randomized, double-blind, placebo-controlled trial of adjunctive probiotic therapy in 66 persons hospitalized with a manic or mixed episode. The active study compound will consist of capsules containing approximately 10\^9 colony forming units of the probiotic organisms, Lactobacillus GG and Bifidobacteria lactis strain Bb12. The dose has been selected because it has been used safely in other probiotic trials, was well-tolerated by the participants in two previous trials of individuals with schizophrenia or mania, and was utilized in the original trial on which this replication is based. This dose is higher than that available in most commercially-sold health food supplements. Following hospital discharge, participants will be randomized to receive adjunctive probiotic or placebo for a 24 week period. It is anticipated that of the 66 participants randomized, \~50 (75%) will complete the full 24 weeks of the study. The primary outcome is relapse, defined as re-hospitalization (e.g., admission to an inpatient unit) for psychiatric symptoms following a previous hospital discharge by at least 2 weeks. The occurrence of new mood episodes, the severity of psychiatric symptoms, and any changes in cognitive test scores over the course of the study will also be evaluated. Changes in the levels of inflammatory markers as well as changes in gut microbiota will be evaluated at three time intervals over the course of the study.
Interventions
- OTHER Placebo
- COMBINATION_PRODUCT Probio-Tec BG-VCap-6.5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2018-09-06 |
| Est. Completion | 2024-09-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03383874
The ClinicalTrials.gov registry entry for NCT03383874 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03383874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03383874 about?
NCT03383874 is a clinical study titled "A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania". This will be a 24-week, randomized, double-blind, placebo-controlled trial of adjunctive probiotic therapy in 66 persons hospitalized with a manic or mixed episode. The active study compound will consist of capsules containing approximately 10\^9 colony forming units of the probiotic organisms, Lact...
What is the current status of trial NCT03383874?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 67 participants. The study started on 2018-09-06. Estimated completion is 2024-09-23.
What interventions are being tested in trial NCT03383874?
The interventions under investigation include: Placebo (OTHER), Probio-Tec BG-VCap-6.5 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03383874?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.